IPH: Marseille-based biotech meets investors in New York and London
In a press release published on October 21, 2026, the Marseille-based biotech announced that members of its management team will engage with the financial community in November. One of these presentations will be subject to live streaming, accessible to the public.
Stifel in New York then Jefferies in London in November
The company listed on Euronext Paris (IPH) and on Nasdaq (IPHA) will first participate in the Stifel Healthcare Conference, held in New York from November 10 to 12, 2026. Its presentation, in the form of an interview, is scheduled for November 10 at 20:00 CET (14:00 New York time).
The link to the live stream will also be available in the "Events" section of the company's Investor Relations area on its website. The recording will be available following the presentation.
Management will then participate in the Jefferies Global Healthcare Conference, which will be held in London from November 16 to 19, 2026.
A portfolio focused on antibody-drug conjugates
The press release, which does not announce any new decisions, recalls the company's strategic direction. Its proprietary portfolio is "centered on antibody-drug conjugates (ADCs)", led by IPH4502, an ADC targeting Nectin-4 in clinical development for solid tumors, complemented by ADC candidates in the preclinical stage.
In parallel, two advanced-stage assets are being developed through partnerships: lacutamab with Sobi in T-cell lymphomas, and monalizumab with AstraZeneca in non-small cell lung cancer. The company also cites collaborations with Sobi, Sanofi and AstraZeneca, as well as with academic and research institutions.
